sevenspikes.themes.common.filters
sevenspikes.themes.common.closemenu

NLG919 (GDC-0919),≥99% (HPLC)

别名:1-环己基-2-(5H-咪唑并[5,1-a]异吲哚-5-基)乙醇;1-cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethanol

CAS:1402836-58-1;分子式:C18H22N2O;分子量:282.38
制造商品牌: BSZH 科学公司
货号(SKU): N06185
CAS号: 1402836-58-1
MDL号: MFCD26142661
增值税发票 √ 免费送货 √ 订货电话:010-68689484
¥826.00

产品描述

本品可溶于DMSO(10mg/ml 加热)和乙醇

General description

一种具有口服活性的IDO1抑制剂,IC50:38nM,具有潜在的免疫调节和抗肿瘤活性。

NLG919  is an orally available inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), with potential immunomodulating and antineoplastic activities. Upon administration, NLG919 targets and binds to IDO1, a cytosolic enzyme responsible for the oxidation of the essential amino acid tryptophan into kynurenine. By inhibiting IDO1 and decreasing kynurenine in tumor cells, this agent increases tryptophan levels, restores the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells, T-lymphocytes, and causes a reduction in tumor-associated regulatory T-cells (Tregs). Activation of the immune system, which is suppressed in many cancers, may induce a cytotoxic T-lymphocyte (CTL) response against the IDO1-expressing tumor cells。

NLG919是一种吲哚胺2,3-二加氧酶1(IDO1)的口服抑制剂,具有潜在的免疫调节和抗肿瘤活性。 给药后,NLG919靶向并与IDO1结合,IDO1是负责将必需氨基酸色氨酸氧化成犬尿氨酸的细胞溶酶。 通过抑制IDO1并减少肿瘤细胞中的犬尿氨酸,该药物可提高色氨酸水平,恢复各种免疫细胞(包括树突状细胞(DC),自然杀伤性(NK)细胞,T淋巴细胞)的增殖和活化,并导致肿瘤减少 相关的调节性T细胞(Tregs)。 在许多癌症中被抑制的免疫系统激活可能诱导针对表达IDO1的肿瘤细胞的细胞毒性T淋巴细胞(CTL)反应。

Properties

Iupac Name1-cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethan-1-ol
Inchi Code1S/C18H22N2O/c21-18(13-6-2-1-3-7-13)10-16-14-8-4-5-9-15(14)17-11-19-12-20(16)17/h4-5,8-9,11-13,16,18,21H,1-3,6-7,10H2
Inchi KeyYTRRAUACYORZLX-UHFFFAOYSA-N


安全信息

风险声明 (欧洲) 23/24/25
安全声明 (欧洲) 26-36
WGK德国 WGK 3
商品规格
属性名称属性值
储存温度 Storage temp.-20°C低温冷冻
全球实时库存 Availability √美国St. Louis ≥ 99 | 欧洲Eur. ≥ 10 | 東京Tokyo ≥ 22 | 香港与北京 ≥ 32